GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GIUp to $440.0 million in milestone payments eligible to be e ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback